High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Background and Aims Recent failures of HDL cholesterol (HDL-C)-raising therapies to prevent cardiovascular disease (CVD) events have tempered the interest in the role of HDL-C in clinical risk assessment. Emerging data suggest that the atheroprotective properties of HDL depend on specific HDL particle characteristics not reflected by HDL-C. The purpose of this study was to determine the association of HDL particle concentration (HDL-P) and HDL subclasses with mortality in a high-risk cardiovascular population and to examine the clinical utility of these parameters in mortality risk discrimination and reclassification models. Methods Using nuclear magnetic resonance spectroscopy, we measured HDL-P and HDL subclasses in 3972 individuals enrolled in the CATHGEN coronary catheterization biorepository; tested for association with all-cause mortality in robust clinical models; and examined the utility of HDL subclasses in incremental mortality risk discrimination and reclassification. Results Over an average follow-up of eight years, 29.6% of the individuals died. In a multivariable model adjusted for ten CVD risk factors, HDL-P [HR, 0.71 (0.67-0.76), p= 1.3e-24] had a stronger inverse association with mortality than did HDL-C [HR 0.93 (0.87-0.99), p=0.02]. Larger HDL size conferred greater risk and the sum of medium- and small-size HDL particles (MS-HDL-P) conferred less risk. Furthermore, the strong inverse relation of HDL-P levels with mortality was accounted for entirely by MS-HDL-P; HDL-C was not associated with mortality after adjustment for MS-HDL-P. Addition of MS-HDL-P to the GRACE Risk Score significantly improved risk discrimination and risk reclassification. Conclusion HDL-P and smaller HDL subclasses were independent markers of residual mortality risk and incremental to HDL-C in a high-risk CVD population. These measures should be considered in risk stratification and future development of HDL-targeted therapies in high-risk populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
HDL cholesterol efflux capacity and incident cardiovascular events
Rohatgi, A., Khera, A., Berry, J. D., Givens, E. G., Ayers, C. R., Wedin, K. E., Neeland, I. J., Yuhanna, I. S., Rader, D. R., de Lemos, J. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409065 · Cited by 1,390 · cited 1×
“Though not feasible in this study, the integration of HDL-P and HDL subclass data along with HDL functional measurements are likely to provide the biggest utility in CVD risk assessment in the future [41].”
BackgroundA prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
HDL and cardiovascular disease
Rader, D. J., & Hovingh, G. K. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61217-4 · Cited by 870
Nicholls, S. J., Brewer, H. B., Kastelein, J. J. P., Krueger, K. A., Wang, M.-D., Shao, M., Hu, B., McErlean, E., & Nissen, S. E. (2011) · JAMA · doi:10.1001/jama.2011.1649 · Cited by 410
Mora, S., Caulfield, M. P., Wohlgemuth, J., Chen, Z., Superko, H. R., Rowland, C. M., Glynn, R. J., Ridker, P. M., & Krauss, R. M. (2015) · Circulation · doi:10.1161/circulationaha.115.016857 · Cited by 126
Sweetnam, P. M., Bolton, C. H., Yarnell, J. W., Bainton, D., Baker, I. A., Elwood, P. C., & Miller, N. E. (1994) · Circulation · doi:10.1161/01.cir.90.2.769 · Cited by 98
Cited by
McGarrah, R. W., Crown, S. B., Zhang, G.-F., Shah, S. H., & Newgard, C. B. (2018) · Circulation Research · doi:10.1161/circresaha.117.311002 · Cited by 423
Self-citationMetabolomics in Diabetes and Diabetic Complications: Insights from Epidemiological Studies
Jin, Q., & Ma, R. C. W. (2021) · Cells · doi:10.3390/cells10112832 · Cited by 252
Updates in Drug Treatment of Severe Hypertriglyceridemia
Gouni-Berthold, I., Schwarz, J., & Berthold, H. K. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01140-z · Cited by 59
“A subsequent NMR-derived lipoprotein size and concentration analysis of this collective [21] showed that total HDL particle concentration increased by 15%, due primarily to a 32% increase in small HDL subspecies, a constellation that has been shown to be inversely related to mortality risk [22].”
BackgroundUpdate on the laboratory investigation of dyslipidemias
Ramasamy, I. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.01.015 · Cited by 50
Metadata
- Authors
- McGarrah, R. W., Craig, D. M., Haynes, C., Dowdy, Z. E., Shah, S. H., & Kraus, W. E.
- Venue
- Atherosclerosis
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 246
- Pages
- 229-235
- ISSN
- 0021-9150 (ISSN-L)
- OpenAlex
- W2285582499
- Cited by
- 77
- References
- 10
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. https://app.cochat.ai/papers/10.1016/j.atherosclerosis.2016.01.012
- The paper
- McGarrah, R. W., Craig, D. M., Haynes, C., Dowdy, Z. E., Shah, S. H., & Kraus, W. E. (2016). High-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort. Atherosclerosis. https://doi.org/10.1016/j.atherosclerosis.2016.01.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.